CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies

CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease Decision Follows Robust Stakeholder Input and Creates Pathway for Enhanced Access and Coverage of Drugs that Receive Traditional FDA Approval Treatment for Alzheimer’s Disease Today, the Centers for Medicare & Medicaid Services (CMS) released a national policy for […]